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Abstract
We report herein a case of a synchronous presentation of an adenocarcinoma of esophagago-
gastric junction type II and an ampullary tumor that was treated by combined Whipple's
pancreaticoduodenectomy, total gastrectomy and esophagectomy. The magnitude of this operation
was safely achieved with meticulous surgical techniques and perioperative care without any major
short or long term complications. Patient returned to a good quality of life at six-month follow up
with no further gastrointestinal symptoms or evidence of disease recurrence.
Background
There has been an increase in the West in recent years of
adenocarcinoma of the esophagus and esophagago-gastric
junction. Standard work-up in high volume centers
includes computed tomography (CT) scan, endoscopic
ultrasound scan (EUS) and [18F]-2-fluoro-2-deoxy-D-glu-
cose-positron emission tomography (18F-FDG-PET) imag-
ing. Adenocarcinoma of the esophago-gastric junction
(AEG) is classified as per Siewert et al. into AEG type I,
arising in the distal esophagus usually on a background of
Barrett's esophagus, AEG type II which arises at the ana-
tomic cardia, and AEG Type III tumors are sub-cardial gas-
tric carcinomas which invade the junction and lower
esophagus from below [1,2]. The surgical approach to
AEG type I tumors most usually involves a transthoracic
esophagectomy with abdominal and mediastinal lym-
phadenectomy. For AEG type II and III, a total gastrec-
tomy and transmediastinal lymphadenectomy and distal
esophagectomy is increasingly utilized [3]. Multimodal
approaches, either chemotherapy alone or combined with
radiation therapy prior to surgery are increasingly consid-
ered for patients with locally advanced disease [4]. The
best 5-year survival for surgery for localized AEG tumors is
approximately 40 per cent [5].
Ampullary cancers, unlike pancreatic carcinomas, may
present at an early stage. The goal of surgical management,
as in all tumors, remains removal of all gross and micro-
scopic disease from the pancreas and draining lymph
node basins [6]. The 5-year survival for completely
resected localized disease is approximately 40 per cent [7].
In this high volume esophageal (50-80 resections/year)
and middle volume pancreatic center (8-15 Whipples/
year) a routine work up of a patient with AEG type II junc-
tional tumor uncovered a synchronous ampullary tumor.
The case and management considerations are discussed
herein.
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Case Presentation
A 62 year old man was referred to our service in 2008 with
a history of epigastric pain and melaena of one week dura-
tion. An upper gastro-intestinal endoscopy revealed an
AEG type II junctional tumour (Figure 1). Biopsies
revealed an invasive moderately differentiated adenocar-
cinoma.
In routine blood tests his liver function tests were noted to
be abnormal, with an AST of 25 IU/L and alkaline phos-
phatase of 201 IU/L. Endoscopic ultrasound revealed a
uT2N0 tumor at the cardia, with one indeterminate peri-
tumoral node. There was also significant dilatation of the
common bile duct (CBD) at the duodenal ampulla and
major pancreatic duct (MPD) (Figure 2). An intra-ampul-
lary homogenous tumor was identified confined to the
ampulla of Vater (Figure 3). CT imaging revealed no evi-
dence of either an esophageal or ampullary tumor, but
there was a double-duct sign of biliary and pancreatic duct
dilatation (Figure 4). 18F-FDG-PET imaging revealed no
abnormal uptake. Endoscopic Retrograde Cholangiopan-
creatography (ERCP) revealed a tumor with a large dis-
torted ampulla (Figure 5) and biopsies revealed high
grade dysplasia and intra mucosal carcinoma.
The patient had good overall performance status. He had
a background history of insulin dependent diabetes mel-
litus with secondary complications including retinopathy
and peripheral neuropathy. His HbA1c on admission was
8.0 g/dL. He also had a history of ischemic heart disease
with subsequent angioplasty in 2006. He had hyperten-
sion, diverticular disease and colonic polyps. A pre-opera-
tive exercise stress test and ECHO revealed good
functional capacity with an ejection fraction of 60-65%.
His FEV1 was 2.37 litres and his FVC was 4.30 litres. Pre-
assessment by the anaesthetist, cardiologist and endo-
crinologist certified patient fit for major operation.
The decision was made to proceed to synchronous resec-
tions with a planned Whipple's, total gastrectomy and dis-
tal esophagectomy, mediastinal dissection and Roux-en-Y
esophago-jejunal reconstruction in that order respectively
via the upper midline laparotomy incision. There was no
technical difficulties in reconstructing the four anastomo-
ses namely hepatico-jejunostomy, pancreatico-jejunos-
tomy, esophago-jejunostomy and jejuno-jejunostomy
An upper gastrointestinal endoscopy showed irregular AGE  Type II junctional tumour with a tongue of Barrett's esopha- gus Figure 1
An upper gastrointestinal endoscopy showed irregu-
lar AGE Type II junctional tumour with a tongue of 
Barrett's esophagus.
EUS demonstrated significant dilatation of both the CBD (12  mm in diameter) and MPD (7 mm in distal portion) Figure 2
EUS demonstrated significant dilatation of both the 
CBD (12 mm in diameter) and MPD (7 mm in distal 
portion).
EUS demonstrated a 12 mm homogeneous ampullary tumour  with no significant loco-regional nodes Figure 3
EUS demonstrated a 12 mm homogeneous ampul-
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(Figure 6). The operation was uneventful, taking 340 min-
utes, the blood loss was 620 mls, and he was extubated
immediately postoperatively. The patient spent 10 days
post operatively in the High Dependency Unit (HDU).
Analgesia was provided via an epidural at the level of T7/
T8 and the patient was given total parenteral nutrition
(TPN). He experienced no major complications and was
discharged home 22 days postoperatively.
Histology of the junctional tumor revealed a 6 mm tumor,
pT1 N0 Mx, with 0 out of 16 nodes involved and negative
margins. The ampullary tumor was invasive adenocarci-
noma, pT1 N0 Mx, and 0 out of 7 nodes were involved.
No adjuvant therapy is being considered. Patient returned
to a good quality of life at six-month follow up with no
further gastrointestinal symptoms or evidence of disease
recurrence.
Discussion
Synchronous presentation of esophago-gastric and peri-
ampullary adenocarcinoma is extremely rare. In a study
by Lee et al., 3.4% of gastric cancers were associated with
synchronous tumors, most commonly colorectal cancer
[7]. Another review of 10,090 patients with gastric cancer
reported that 96 had synchronous tumors and 5 of those
were pancreatic carcinoma [8]. The management of a case
of squamous cell carcinoma (SCC) of the esophagus with
an intraductal pancreatic polypoid tumor has been
reported, as well as a case of SCC of the esophagus with
adenocarcinoma of the ampulla of Vater [9,10]. There was
a report on technical challenges in avoiding injury to the
middle colic vessels with successful pancreaticoduodenec-
tomy for carcinoma of the ampulla of Vater after
esophagectomy with remnant gastrectomy 17 years prior
[11]. To our knowledge there is no reported case of syn-
chronous adenocarcinoma of the esophago-gastric junc-
tion and ampullary adenocarcinoma.
Abdominal Computed Tomography showed the double duct  sign Figure 4
Abdominal Computed Tomography showed the dou-
ble duct sign.
Endoscopic view during ERCP showed a large ampullary  tumour Figure 5
Endoscopic view during ERCP showed a large ampul-
lary tumour.
A drawing illustrating the liver (L), pancreas (P), hepatico- jejunostomy (H-J), pancreatico-jejunostomy (P-J), esophago- jejunostomy (E-J) and jejuno-jejunostomy (J-J) anastomoses Figure 6
A drawing illustrating the liver (L), pancreas (P), 
hepatico-jejunostomy (H-J), pancreatico-jejunostomy 
(P-J), esophago-jejunostomy (E-J) and jejuno-jejunos-
tomy (J-J) anastomoses.Patient Safety in Surgery 2009, 3:23 http://www.pssjournal.com/content/3/1/23
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For both tumors independently, surgical resection is the
only curative approach, and the risk of mortality for each
procedure should be less than 5 per cent in high-volume
centers. Neoadjuvant chemotherapy or chemoradiother-
apy for AEG type II junctional adenocarcinoma was dis-
cussed but not pursued since this appeared localized and
node-negative with a high probability of an R0 resection
[12]. The role of perioperative chemotherapy based on
MAGIC trial probably offer little benefit in altering
resectability, progression-free survival and overall survival
of this early stage AEG type II junctional tumour [13]. The
risk of adverse effects of haematological and non-haema-
tological toxicity associated with perioperative chemo-
therapy was considered and discussed.
The surgical treatment options considered in our patient
were combined Whipple's pancreaticoduodenectomy,
total gastrectomy, distal esophagectomy and Roux-en-Y
esophago-jejunal reconstruction along with hepatico-jeju-
nostomy, pancreatico-jejunostomy and jejuno-jejunos-
tomy. We were prepared to do a thoracotomy to get
adequate clearance if required, but splitting the dia-
phragm and a mediastinal dissection and anastomosis
were achievable via the abdominal incision. Increasing
evidence supports the rationale to avoid transthoracic sur-
gery for AEG type II tumors which are predominantly of
gastric origin and rarely involve high mediastinal or sub-
carinal nodes [1,3].
For the ampulla, the EUS and ERCP were more in keeping
with an invasive rather than an in situ cancer, and a local
resection was not considered. A pylorus -preserving
approach with gastric preservation combined with a prox-
imal gastrectomy and esophagectomy would have been
technically possible, but functional results from total gas-
trectomy with Roux-en-Y esophago-jejunal reconstruction
may be better due to the risk of reflux esophagitis. There
appears to be only one previous report in the literature of
a similar procedure for synchronous tumors. Mafune et al.
described a case of subtotal esophagectomy for SCC, pan-
creaticoduodenectomy with lymph node dissection and
total residual gastrectomy in a patient who had a previous
gastrectomy [10].
Synchronous resection of AEG type II junctional tumour
and ampullary tumour appears attractive although it takes
longer to perform, the benefits are having one general
anaesthesia for four anastomotic reconstructions and thus
avoiding a second major operation. Whilst a staged proce-
dure may take shorter to perform, the risks are two general
anesthesia with potential adhesions complicating second
stage procedure and the potential delay in resection of sec-
ond rapidly progressing tumour. Suzuki et al. reported
simultaneous resection of synchronous esophageal and
extraesophageal carcinomas can be safely performed with
no significant difference in morbidity and mortality com-
pared to solitary esophageal cancer resection as long as
complete clearance of both tumours is achieved for
favourable long-term results [14].
Conclusion
This is the first report of combined Whipple's and
esophago-gastrectomy for these synchronous tumors. The
magnitude of this operation was safely achieved with
meticulous surgical techniques and perioperative care
without any major complications.
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